INTEGRA LIFESCIENCES HOLDING (IART) Stock Fundamental Analysis
USA - NASDAQ:IART - US4579852082 - Common Stock
16.12 USD
+0.24 (+1.51%)
16.12 USD
0 (0%)
Overall IART gets a fundamental rating of 3 out of 10. We evaluated IART against 190 industry peers in the Health Care Equipment & Supplies industry. There are concerns on the financial health of IART while its profitability can be described as average. IART has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
IART had positive earnings in the past year.
IART had a positive operating cash flow in the past year.
IART had positive earnings in 4 of the past 5 years.
IART had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -13.65%, IART perfoms like the industry average, outperforming 55.79% of the companies in the same industry.
IART's Return On Equity of -48.20% is in line compared to the rest of the industry. IART outperforms 50.00% of its industry peers.
IART has a Return On Invested Capital of 4.68%. This is in the better half of the industry: IART outperforms 76.32% of its industry peers.
IART had an Average Return On Invested Capital over the past 3 years of 6.10%. This is below the industry average of 8.88%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.65% | ||
| ROE | -48.2% | ||
| ROIC | 4.68% |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
1.3 Margins
IART's Operating Margin of 9.46% is fine compared to the rest of the industry. IART outperforms 77.37% of its industry peers.
In the last couple of years the Operating Margin of IART has declined.
With a Gross Margin value of 57.24%, IART perfoms like the industry average, outperforming 55.26% of the companies in the same industry.
IART's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.46% | ||
| PM (TTM) | N/A | ||
| GM | 57.24% |
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IART is still creating some value.
IART has less shares outstanding than it did 1 year ago.
The number of shares outstanding for IART has been reduced compared to 5 years ago.
IART has a worse debt/assets ratio than last year.
2.2 Solvency
IART has an Altman-Z score of 1.10. This is a bad value and indicates that IART is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 1.10, IART perfoms like the industry average, outperforming 50.53% of the companies in the same industry.
A Debt/Equity ratio of 1.18 is on the high side and indicates that IART has dependencies on debt financing.
IART has a Debt to Equity ratio of 1.18. This is in the lower half of the industry: IART underperforms 78.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.18 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.1 |
ROIC/WACC0.8
WACC5.89%
2.3 Liquidity
A Current Ratio of 1.23 indicates that IART should not have too much problems paying its short term obligations.
With a Current ratio value of 1.23, IART is not doing good in the industry: 80.53% of the companies in the same industry are doing better.
IART has a Quick Ratio of 1.23. This is a bad value and indicates that IART is not financially healthy enough and could expect problems in meeting its short term obligations.
IART has a Quick ratio of 0.73. This is amonst the worse of the industry: IART underperforms 86.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.23 | ||
| Quick Ratio | 0.73 |
3. Growth
3.1 Past
The earnings per share for IART have decreased strongly by -20.85% in the last year.
IART shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.35% yearly.
Looking at the last year, IART shows a small growth in Revenue. The Revenue has grown by 3.53% in the last year.
Measured over the past years, IART shows a small growth in Revenue. The Revenue has been growing by 1.20% on average per year.
EPS 1Y (TTM)-20.85%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%-28.57%
Revenue 1Y (TTM)3.53%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%-0.61%
3.2 Future
IART is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.21% yearly.
The Revenue is expected to grow by 3.88% on average over the next years.
EPS Next Y-11.85%
EPS Next 2Y-1.83%
EPS Next 3Y2.21%
EPS Next 5YN/A
Revenue Next Year3.53%
Revenue Next 2Y3.93%
Revenue Next 3Y3.88%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 7.20, which indicates a rather cheap valuation of IART.
Based on the Price/Earnings ratio, IART is valued cheaply inside the industry as 97.37% of the companies are valued more expensively.
IART's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.91.
Based on the Price/Forward Earnings ratio of 6.53, the valuation of IART can be described as very cheap.
IART's Price/Forward Earnings ratio is rather cheap when compared to the industry. IART is cheaper than 98.42% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.92. IART is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.2 | ||
| Fwd PE | 6.53 |
4.2 Price Multiples
IART's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. IART is cheaper than 92.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 9.24 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.83%
EPS Next 3Y2.21%
5. Dividend
5.1 Amount
No dividends for IART!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
16.12
+0.24 (+1.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners95.73%
Inst Owner Change-1.01%
Ins Owners3.04%
Ins Owner Change1.47%
Market Cap1.26B
Revenue(TTM)1.62B
Net Income(TTM)-500626000
Analysts54.12
Price Target16.76 (3.97%)
Short Float %9.6%
Short Ratio4.93
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.27%
Min EPS beat(2)-6.76%
Max EPS beat(2)2.22%
EPS beat(4)3
Avg EPS beat(4)2.45%
Min EPS beat(4)-6.76%
Max EPS beat(4)11.12%
EPS beat(8)3
Avg EPS beat(8)-0.11%
EPS beat(12)6
Avg EPS beat(12)3.26%
EPS beat(16)8
Avg EPS beat(16)3.79%
Revenue beat(2)1
Avg Revenue beat(2)0.78%
Min Revenue beat(2)-1.58%
Max Revenue beat(2)3.14%
Revenue beat(4)1
Avg Revenue beat(4)-0.4%
Min Revenue beat(4)-2.51%
Max Revenue beat(4)3.14%
Revenue beat(8)1
Avg Revenue beat(8)-0.95%
Revenue beat(12)2
Avg Revenue beat(12)-0.82%
Revenue beat(16)3
Avg Revenue beat(16)-0.75%
PT rev (1m)0%
PT rev (3m)-1.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-24.66%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)-1.21%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.18%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.2 | ||
| Fwd PE | 6.53 | ||
| P/S | 0.77 | ||
| P/FCF | N/A | ||
| P/OCF | 17.72 | ||
| P/B | 1.21 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.24 |
EPS(TTM)2.24
EY13.9%
EPS(NY)2.47
Fwd EY15.31%
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)0.91
OCFY5.64%
SpS20.82
BVpS13.33
TBVpS-9.83
PEG (NY)N/A
PEG (5Y)N/A
Graham Number25.92
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.65% | ||
| ROE | -48.2% | ||
| ROCE | 5.61% | ||
| ROIC | 4.68% | ||
| ROICexc | 5.16% | ||
| ROICexgc | 18.86% | ||
| OM | 9.46% | ||
| PM (TTM) | N/A | ||
| GM | 57.24% | ||
| FCFM | N/A |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
ROICexc(3y)6.8%
ROICexc(5y)7%
ROICexgc(3y)25.35%
ROICexgc(5y)25.69%
ROCE(3y)7.3%
ROCE(5y)7.36%
ROICexgc growth 3Y-1.99%
ROICexgc growth 5Y0.59%
ROICexc growth 3Y-12.19%
ROICexc growth 5Y-7.26%
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
F-Score5
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.18 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 4.06 | ||
| Cap/Depr | 79.68% | ||
| Cap/Sales | 7.29% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 23.48% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.23 | ||
| Quick Ratio | 0.73 | ||
| Altman-Z | 1.1 |
F-Score5
WACC5.89%
ROIC/WACC0.8
Cap/Depr(3y)58.38%
Cap/Depr(5y)54.07%
Cap/Sales(3y)4.82%
Cap/Sales(5y)4.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.85%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%-28.57%
EPS Next Y-11.85%
EPS Next 2Y-1.83%
EPS Next 3Y2.21%
EPS Next 5YN/A
Revenue 1Y (TTM)3.53%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%-0.61%
Revenue Next Year3.53%
Revenue Next 2Y3.93%
Revenue Next 3Y3.88%
Revenue Next 5YN/A
EBIT growth 1Y-36.46%
EBIT growth 3Y-13.07%
EBIT growth 5Y-6.81%
EBIT Next Year17.98%
EBIT Next 3Y9.96%
EBIT Next 5YN/A
FCF growth 1Y-130.53%
FCF growth 3Y-61.56%
FCF growth 5Y-31.13%
OCF growth 1Y-65.94%
OCF growth 3Y-25.46%
OCF growth 5Y-10.98%
INTEGRA LIFESCIENCES HOLDING / IART FAQ
Can you provide the ChartMill fundamental rating for INTEGRA LIFESCIENCES HOLDING?
ChartMill assigns a fundamental rating of 3 / 10 to IART.
Can you provide the valuation status for INTEGRA LIFESCIENCES HOLDING?
ChartMill assigns a valuation rating of 6 / 10 to INTEGRA LIFESCIENCES HOLDING (IART). This can be considered as Fairly Valued.
How profitable is INTEGRA LIFESCIENCES HOLDING (IART) stock?
INTEGRA LIFESCIENCES HOLDING (IART) has a profitability rating of 4 / 10.
What is the financial health of INTEGRA LIFESCIENCES HOLDING (IART) stock?
The financial health rating of INTEGRA LIFESCIENCES HOLDING (IART) is 2 / 10.